POTASSIUM CITRATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM CITRATE (POTASSIUM CITRATE).
Alkalizing agent that increases urinary pH and citrate concentration; citrate chelates calcium in urine, reducing calcium oxalate and calcium phosphate supersaturation. Also provides potassium to correct hypokalemia.
| Metabolism | Metabolized primarily via the tricarboxylic acid (TCA) cycle; undergoes oxidation to bicarbonate, generating an alkalizing effect. |
| Excretion | Renal: >99% as citrate, potassium, and bicarbonate; minimal fecal or biliary elimination. |
| Half-life | Not applicable as potassium citrate is not metabolized; urinary citrate excretion follows first-order kinetics with an effective half-life of approximately 2-3 hours for renal elimination. |
| Protein binding | <5% (citrate not significantly protein-bound; potassium is freely filtered). |
| Volume of Distribution | 0.2-0.4 L/kg (reflects distribution primarily in extracellular fluid). |
| Bioavailability | Oral: ~100% (well-absorbed; citrate is completely absorbed and metabolized to bicarbonate). |
| Onset of Action | Oral: 2-4 hours for significant increase in urinary citrate excretion; IV (if applicable): immediate. |
| Duration of Action | Oral: Up to 8-12 hours; urine alkalinization peaks at 4-6 hours and declines over 12 hours. |
10-20 mEq (as potassium) orally three times daily with meals; maximum 100 mEq/day. Each gram of potassium citrate provides 9.25 mEq of potassium.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | Contraindicated in GFR < 30 mL/min/1.73 m2 due to risk of hyperkalemia. For GFR 30-50 mL/min/1.73 m2, reduce dose by 50% and monitor serum potassium frequently. |
| Liver impairment | No specific Child-Pugh based dose adjustments; use with caution in severe hepatic impairment due to potential acid-base disturbances. |
| Pediatric use | 2-4 mEq/kg/day in 3-4 divided doses as potassium citrate solution; maximum 6 mEq/kg/day. Monitor serum potassium closely. |
| Geriatric use | Start at low end of dosing range (10 mEq three times daily) due to age-related decline in renal function. Monitor renal function and serum potassium regularly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CITRATE (POTASSIUM CITRATE).
| Breastfeeding | Potassium is a normal component of breast milk. Exogenous potassium citrate ingestion is unlikely to significantly alter milk potassium concentration. M/P ratio not established. Generally considered compatible with breastfeeding when maternal potassium levels are within normal limits. |
| Teratogenic Risk | Pregnancy Category C. No controlled human studies. In animal studies, potassium citrate administered at high doses did not demonstrate teratogenicity but did cause maternal toxicity and reduced fetal weight. First trimester: theoretical risk of hyperkalemia-induced fetal arrhythmia. Second/third trimester: risk of maternal hyperkalemia causing fetal bradycardia. Use only if clearly needed. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hyperkalemia (serum potassium > 5.5 mEq/L)","Severe renal impairment (CrCl < 30 mL/min)","Addison's disease or other adrenal insufficiency","Concomitant use with potassium-sparing diuretics","Active peptic ulcer disease","Urinary tract infections (UTIs) with urease-producing organisms (e.g., Proteus, Pseudomonas)"]
| Precautions | ["Use with caution in patients with renal impairment (creatinine clearance < 60 mL/min) due to risk of hyperkalemia and aluminum toxicity from concomitant aluminum-containing products","Monitor serum electrolytes and renal function periodically","Avoid in patients with severe hepatic dysfunction","May cause gastrointestinal adverse effects; tablets should be taken with meals and a full glass of water"] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium, creatinine, and electrocardiogram (ECG) periodically. In pregnancy, monitor maternal blood pressure and uterine activity if potassium levels approach upper normal limits. Fetal monitoring with non-stress test or biophysical profile if maternal hyperkalemia suspected. |
| Fertility Effects | No known direct effects on fertility. Hypokalemia from underlying conditions (e.g., renal tubular acidosis) may impair fertility; correction with potassium citrate restores normal reproductive function. |